On September 14, 2023, Charles River Laboratories International, Inc. and Related Sciences, a data science-driven drug discovery firm, announced a multi-program collaboration agreement to apply Logica™—an AI-powered drug solution that translates biological insights into optimized assets—across several previously undrugged targets in the Related Sciences portfolio. Wilson Sonsini Goodrich & Rosati advised Related Sciences on the transaction.

Under the collaboration, Related Sciences will work closely with the Charles River and Valo Health teams to deploy Logica to discover valuable new medicines to address key unmet needs across a range of disease areas, including cancer immunotherapy, autoimmunity, and inflammatory diseases. Charles River and Valo Health launched Logica in 2022, leveraging the AI-powered Valo Opal Computational Platform™ and Charles River’s leading preclinical expertise to provide clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination.

Wilson Sonsini technology transactions partner Seth Flaum advised Related Sciences on the collaboration.

For more information, please see the companies’ news release.